MaxCyte to Delist from AIM and Focus on NASDAQ Listing

PUBLISHED: Apr 28 2025 @ 03:24 | Comments (0) | More info about Fiona Craig

MaxCyte, Inc. (LSE:MXCT) has announced its decision to delist its ordinary shares from AIM, with plans to file a definitive proxy statement to obtain stockholder approval for the move. This strategic shift aims to streamline the company’s market presence and prioritize its NASDAQ listing, focusing trading activities on a single exchange. The delisting is part of MaxCyte’s broader strategy to concentrate its efforts on its growth in the U.S. market.

About MaxCyte, Inc.

MaxCyte is a leading company in the field of cell engineering, offering advanced platform technologies that aid in the discovery, development, and commercialization of next-generation cell-based therapies. The company’s ExPERT platform, built on Flow Electroporation technology, plays a crucial role in supporting the growth of the cell therapy market, with a portfolio of instruments and proprietary processing assemblies.

Year-to-Date Price Performance: -34.57%
Average Daily Trading Volume: 34,074 shares
Technical Sentiment Indicator: Buy
Current Market Capitalization: £230.5 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.